BRD3

Bromodomain-containing protein 3

67,521 patent compounds predicted against BRD3, 45,445 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL224361	0.61	19/20
SCHEMBL223599	0.56	19/20
SCHEMBL224890	0.56	19/20
SCHEMBL224891	0.56	19/20
SCHEMBL222873	0.54	19/20
SCHEMBL222924	0.50	19/20
SCHEMBL224065	0.58	18/20
SCHEMBL223065	0.53	18/20
SCHEMBL220739	0.51	18/20
SCHEMBL220740	0.51	18/20
SCHEMBL221491	0.66	17/20
SCHEMBL225875	0.66	17/20
SCHEMBL223799	0.64	17/20
SCHEMBL224292	0.64	17/20
SCHEMBL223665	0.60	17/20
SCHEMBL221283	0.56	17/20
SCHEMBL222018	0.56	17/20
SCHEMBL224960	0.56	17/20
SCHEMBL224961	0.56	17/20
SCHEMBL223323	0.55	17/20

Germline variants in BRD3 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full BRD3 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to BRD3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD	PHASE3	COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma	PHASE1/PHASE2	RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Vorinostat in Children	PHASE1/PHASE2	COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma	PHASE2	COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer	PHASE2	UNKNOWN
A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.	PHASE1	COMPLETED
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors	PHASE1	RECRUITING
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma	PHASE1	COMPLETED
Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors	PHASE1	UNKNOWN
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer	PHASE1	RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	EARLY_PHASE1	RECRUITING
Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor	nan	NO_LONGER_AVAILABLE
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL	nan	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a BRD3 binder may also engage these)

Protein	Name	Similarity
Q8K2F0	—	1.000	Q8K2F0 →
Q32S26	—	0.997	Q32S26 →
Q5TJG6	—	0.996	Q5TJG6 →
BRD2	Bromodomain-containing protein 2	0.995	landscape →
Q6MGA9	—	0.993	Q6MGA9 →
Q7JJ13	—	0.992	Q7JJ13 →
Q9ESU6	—	0.989	Q9ESU6 →
Q08D75	—	0.986	Q08D75 →
BRD4	Bromodomain-containing protein 4	0.986	landscape →
Q6DFF2	—	0.986	Q6DFF2 →
F1R5H6	—	0.985	F1R5H6 →
SMARCC2	SWI/SNF complex subunit SMARCC2	0.985	landscape →
Q8CGF7	—	0.984	Q8CGF7 →
Q3UQU0	—	0.982	Q3UQU0 →
Q9Y7N0	—	0.982	Q9Y7N0 →
SMARCC1	SWI/SNF complex subunit SMARCC1	0.981	landscape →
Q6PDG5	—	0.981	Q6PDG5 →
P97496	—	0.981	P97496 →
P35817	—	0.981	P35817 →
O75061	—	0.981	O75061 →
Q09YG9	—	0.981	Q09YG9 →
Q09YJ3	—	0.981	Q09YJ3 →
Q870Q1	—	0.981	Q870Q1 →
U2SURP	U2 snRNP-associated SURP motif-containing protein	0.980	landscape →
Q2IBF8	—	0.980	Q2IBF8 →
Q17FR9	—	0.980	Q17FR9 →
Q2T9I5	—	0.980	Q2T9I5 →
Q8IWZ8	—	0.980	Q8IWZ8 →
Q8CJH2	—	0.980	Q8CJH2 →
Q32NW2	—	0.980	Q32NW2 →